Cardiovascular disease is the leading cause of death and disability in Europe. Several large, population-based trials and their meta-analyses have shown the beneficial effects of statins in reducing mortality and cardiovascular morbidity both primary and secondary prevention. Use of generic drugs, which are bioequivalent to brand-name drugs, can help contain prescription drug spending.
FDA bioequivalence rating as a proxy for clinical equivalence among a number of important cardiovascular drugs, even in higher-risk contexts such as the NTI drug warfarin.
Related Journals of Bioequivalence Cardiovascular Products
Indian Journal of Pharmaceutical Research, International Journal of BioAnalytical Methods & BioEquivalence Studies, Cardiovascular Pharmacology: Open Access, Journal of Bioequivalence & Bioavailability, MOJ Bioequivalence & Bioavailability, Bioanalytical Methods & Bioequivalence Studies, Enliven: Biosimilars and Bioavailablity, International Journal of Pharmaceutical and Biomedical Research, Chemical Speciation & Bioavailability, Journal of Bioanalysis & Biomedicine, Journal of Molecular Pharmaceutics & Organic Process Research.